Onxeo SA Earnings Estimate

Onxeo SA Earnings per Share Projection vs Actual

About Onxeo SA Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Onxeo SA earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Onxeo SA estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Onxeo SA fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. Onxeo SA was incorporated in 1997 and is headquartered in Paris, France. ONXEO S operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 29 people.

Currently Active Assets on Macroaxis

Other Information on Investing in Onxeo Stock

Onxeo SA financial ratios help investors to determine whether Onxeo Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Onxeo with respect to the benefits of owning Onxeo SA security.